血液透析患者应用促红细胞生成素治疗贫血的疗效观察及年龄影响因素分析

The effect observation and factor analisis on age of erythropoietin in treatment of hemodialysis patient with anemia

目的观察促红细胞生成素对血液透析患者贫血的疗效,并按年龄因素对疗效进行分析。方法对238例血液透析贫血患者应用促红细胞生成素3000U支/皮下注射,剂量每周100~150U/kg,分2~3次给药。分析其疗效并与年龄的关系。结果 238例患者中有效224例（94.12%）,无效14例（5.88%）。治疗后238例患者血红蛋白（Hb）、红细胞比容（Hct）、尿素氮（BUN）及肌酐（Cr）水平明显改善（P〈0.01）,贫血改善情况随年龄的增加而下降（P〈0.05或P〈0.01）。对Hb上升值及年龄因素进行Pearson相关分析表明,Hb上升值及年龄因素呈负相关（r=-0.682）。且不良反应轻微。结论促红细胞生成素治疗血液透析患者贫血安全有效,但疗效随年龄增加而下降。

Objective To observation the effect of erythropoietin in treatment of hemodialysis patient with anemia,and analysis the effect by age factor. Methods 238 cases hemodialysis patient with anemia gave erythropoietin 3000U subcutaneously, 100-150U/kg ever week. Analysised the effect and the influence of age factor. Results In 238 cases patients,effective 224 cases （ 94.12% ） , ineffective 14 cases （ 5.88 % ）. After treatment, the levels of hemoglobin （ Hb ）, hematocrit （ Het ）, blood urea nitrogen （BUN） and creatinine（Cr） in 238 cases patients significantly improved（P 〈 0.01 ） ; Improvement of anemia de- creased with age increasing（ P 〈0.05 or P 〈0.01 ）. Appreciation of Hb and age factors on the Pearson correlation analysis,Hb and age factors on the appreciation of the negative correlation （ r = - 0. 682 ）. Conclusion Erythropoietin can improve the symptoms of bemodialysis patient with anemia,but the efficacy reduce with the age increasing.